News

News

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid TumorsLead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trialsDesigned for systemic delivery, high selectivity, and enhanced tumor accessVCN-01 granted Orphan Drug Designation in Pancreatic Cancer by the EMASynthetic Biologics and VCN Biosciences to host a conference call today, December 14th, at 10:00 a.m. Eastern Time

For Immediate Release

Barcelona, November 2nd, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the oral presentation at the upcoming 2021 International Oncolytic Virus Conference (IOVC) being held November 5-7, 2021, both virtually and in Sedona, Arizona.

Barcelona, February 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced that VCN-01 at a dose of 3.3x1012 vp/patient can be safely administered in combination with Durbalumab when administered 15 days apart. Accordingly, in an Investigator Meeting, it was decided that VCN-01 will be further investigated at a higher dose of 1x1013 vp/patient in combination with Durvalumab.

Barcelona, March 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the publication of preclinical research on promising therapy VCN-11 in Peer-Reviewed Journal of Controlled Release.

Barcelona, November 27, 2020 – A team of researchers from SJD BarcelonaA team of researchers from SJD BarcelonaChildren’s Hospital and the biotechnology company VCN Biosciences, a Grifols company,has developed a world-first treatment which has prevented a child, who hadalready lost an eye to retinal cancer, from losing the other eye and becomingcompletely blind. As a result, Félix, who travelled from Venezuela to Barcelonaspecifically for the treatment, is now disease-free and retains his visual acuity, allowinghim to walk and play just as before. The treatment, which was administered as part ofa clinical trial, consists in injecting a genetically modified virus into the tumour-affectedeye. This virus can select, attack and destroy cancer cells.

January, 2019 -A team of researchers from SJD Barcelona Children’s Hospital has developed a new experimental treatment for retinoblastoma or tumour of the retina, a disease that accounts for 11% of malignancies in children under one year old. The treatment consists of injecting a genetically modified virus into the eye affected by the tumour.

November, 2016 – VCN Biosciences, a clinical –stage company developing oncolytic immunoncology products, is pleased to announce that preliminary clinical data on the Fist-in-Man Phase 1 clinical trial of VCN-01 after a single intravenous injection, either alone or combined with nab-paclixatel/gemcitabine will be presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, one of the world foremost oncology conferences on the latest developments in targets and drugs for cancer.

July, 2013 -VCN Biosciences was invited to present its recent results on the chemosensitization capabilities to gemcitabine of its lead candidate VCN-01 in the framework of the 7th edition of the International Meeting On Replicating Oncolytic Virus Therapeutics, that was held during June 15th to 18th in Old Quebec City, Quebec (Canada).

May 2012 -VCN Biosciences, a company specialized in the development of new biotechnological products for the treatment of cancer, completed last winter a round of consultation with the European Medicines Agency (EMA) and the Spanish Medicines Authorities (AEMPS) to discuss the proposed development for VCN-01, its most advanced candidate for treatment of pancreatic cancer.

June, 2011. -VCN Biosciences, a catalan biotechcompany focused in the development of new antitumoral agents for the treatment of human tumors that lack effective therapy, has recently obtained the granting for Orphan Medicinal Product for its more advanced clinical candidate VCN-01 in the treatment of human pancreatic carcinoma by the Committee for Orphan Medicinal Products (COMB) from EMA (European Medicines Agency).

July, 2010 - “ORCA Therapeutics B.V. a biopharmaceutical company in the field of virotherapy, today announced that it obtained an exclusive license from VCN Biosciences L.S. in Gelida (Barcelona), Spain, to their T1 oncolytic adenovirus technology for the treatment of cancer.

Mobile menu